Clinical trial
Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast…
NCT00039520 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00039520 |
|---|---|
| Title | Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer |
| Official title | A Phase II Trial Of Exisulind With Docetaxel In Patients With Metastatic Adenocarcinoma Of The Breast |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, sulindac |
| Enrollment | 10 |
| Start date | Jan 1, 2002 |
| Primary completion | Jun 1, 2004 |
| Completion | Jul 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | May 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: